GlassScriptPhysician profile
Christina N Bergstrom
NPI 1588811467
$6,196.92
in general payments reported to CMS, 2019-2025
44 companies · $2,278 in 2025
The $2,278 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.07 · 2020: $400 · 2021: $689 · 2022: $786 · 2023: $829 · 2024: $1,199 · 2025: $2,278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,300 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,299.69 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,069.64 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $688.61 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $574.19 | 2021-2025 | Ubrelvy, Qulipta |
| Pfizer INC. | $503.24 | 2020-2025 | |
| Lilly USA, LLC | $485.60 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $402.35 | 2021-2025 | Evenity, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $382.51 | 2020-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $246.46 | 2022-2025 | |
| Glaxosmithkline, LLC. | $216.50 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Insulet Corporation | $150.00 | 2025 | Omnipod |
| Madrigal Pharmaceuticals | $108.55 | 2025 | Rezdiffra |
| Lundbeck LLC | $82.57 | 2023-2024 | Rexulti |
| Exact Sciences Corporation | $80.63 | 2023-2025 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $80.02 | 2021-2024 | Injectafer |
| Novartis Pharmaceuticals Corporation | $78.34 | 2022-2024 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Bergstrom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.